Herring WL, Mauskopf J. Persistent Challenges in Alzheimer’s Disease Modeling: Pragmatic Solutions to Inform the Road Forward. RTI Health Solutions, retrieved from http://www.rtihs.org on January 2020.
Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):563-570. doi: 10.1080/14737167.2020.1822738.
Mauskopf J, Herring W, Zhang Y, Tahami A. The variability in structural assumptions in models estimating the effectiveness of hypothetical disease modifying treatment for Alzheimer’s disease. Value in Health, Volume 22, Issue S1 (2019 May)
Nguyen KH, Comans TA, Green C. Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment. Int Psychogeriatr. 2018 Nov;30(11):1593-1605. doi: 10.1017/S1041610218001291.
Sanjib Saha, Ulf-G. Gerdtham, Håkan Toresson, Lennart Minthon, Johan Jarl. Economic Evaluation of Interventions for Screening of Dementia. Working Paper 2018:20 Department of Economics School of Economics and Management Lund University
Handels R, Wimo A. Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia. Aging Ment Health. 2019 Jan;23(1):53-59. doi: 10.1080/13607863.2017.1390730. Epub 2017 Oct 17.
Sopina E, Sørensen J. Decision modelling of non-pharmacological interventions for individuals with dementia: a systematic review of methodologies. Health Econ Rev. 2018 Mar 26;8(1):8. doi: 10.1186/s13561-018-0192-8.
Gustavsson A, Green C, Jones RW, Förstl H, Simsek D, de Reydet de Vulpillieres F, Luthman S, Adlard N, Bhattacharyya S, Wimo A. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. Alzheimers Dement. 2017 Mar;13(3):312-321. doi: 10.1016/j.jalz.2016.12.005.
Hernandez L, Ozen A, DosSantos R, Getsios D. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease. Pharmacoeconomics. 2016 Jul;34(7):681-707. doi: 10.1007/s40273-016-0392-1.
Green C, Zhang S. Predicting the progression of Alzheimer’s disease dementia: A multidomain health policy model. Alzheimers Dement. 2016 Jul;12(7):776-85. doi: 10.1016/j.jalz.2016.01.011.
Handels RL, Wolfs CA, Aalten P, Joore MA, Verhey FR, Severens JL. Diagnosing Alzheimer’s disease: a systematic review of economic evaluations. Alzheimers Dement. 2014 Mar;10(2):225-37.
Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165.
Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer’s disease: a systematic review of cost-effectiveness analyses. Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
Green C, Shearer J, Ritchie CW, Zajicek JP. Model-based economic evaluation in Alzheimer’s disease: a review of the methods available to model Alzheimer’s disease progression. Value Health. 2011 Jul-Aug;14(5):621-30.
Oremus M. Systematic review of economic evaluations of Alzheimer’s disease medications. Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):273-89. doi: 10.1586/14737167.8.3.273.
Cohen JT, Neumann PJ. Decision analytic models for Alzheimer’s disease: state of the art and future directions. Alzheimers Dement. 2008 May;4(3):212-22.
Green C. Modelling disease progression in Alzheimer’s disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics. 2007;25(9):735-50.
Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160.
IPECAD 